Table 4.
Factors affecting the local tumor recurrence within 1 year in 22 patients after RFA.
| Local recurrence (n = 3) | No local recurrence(n = 19) | P | |
| Age (yr) | 57.7±9.3 | 63.3±11.6 | NS6 |
| Sex (Male/Female) | 2/1 | 14/5 | NS |
| Child1 (A/B) | 3/0 | 15/4 | NS |
| Right lobe/Left lobe | 2/1 | 14/5 | NS |
| Subcapsular (+/-) | 1/2 | 3/16 | NS |
| HBV/HCV/others | 1/2/0 | 8/8/3 | NS |
| EV2 (+/-) | 1/2 | 10/9 | NS |
| Tumor size (cm) | 3.2±0.7 | 2.2±0.7 | 0.03 |
| Tumor >2 cm (+/-) | 3/0 | 9/10 | 0.089 |
| Histology | |||
| (Well/Poor)3 | 2/1 | 19/0 | 0.01 |
| BCLCstage4 Ia/Ib/Ic | 1/1/1 | 10/9 | 0.036 |
| Roll-off (+/-) | 3/0 | 18/1 | NS |
| Ablative time (min) | 27.0±12.3 | 20.4±14.0 | NS |
| Sessions | 1.3±0.6 | 1.2±0.4 | NS |
| Follow-up (mo) | 35.0±6.6 | 27.8±9.1 | NS |
| Pre-RFA/Post-RFA | |||
| Albumin (g/dL) | 3.6±0.3/4.0±1.0 | 3.9±0.5/4.2±0.5 | NS/NS |
| T. Bili. (mg/dL) | 1.2±0.6/1.1±0.2 | 1.0±0.5/1.0±0.5 | NS/NS |
| GOT (U/L) | 56.3±16.2/49.3±14.0 | 64.6±34.9/73.3±35.4 | NS/NS |
| GPT (U/L) | 50.0±24.4/56.3±20.1 | 74.4±41.4/82.8±34.9 | NS/NS |
| Alk-P (U/L) | 106.3±26.3/109.3±31.0 | 117.6±49.1/125.7±48.3 | NS/NS |
| AFP5 (ng/mL) | 967.7±1647.5/145.0±240.0 | 106.0±323.3/24.9±33.3 | NS/NS |
| Decrease AFP > 50% | 2/1 | 6/13 | NS |
| Post-RFA(+/-) |
1
Child: child-Pugh classification
2
EV: esophageal varices
3
Well/Poor: well differentiated/Poor differentiated
4
BCLC stage: staging system from conclusions of the Barcelona-2000 EASL conference[16]
5
AFP: alpha-fetoprotein
6
NS: not significant.